Mexiletine HCl
Catalog No.S4225 Synonyms: KO1173
Molecular Weight(MW): 215.72
Mexiletine HCl belongs to Class IB anti-arrhythmic group of medicines, inhibits sodium channels to reduce the inward sodium current.
Purity & Quality Control
Choose Selective Sodium Channel Inhibitors
Biological Activity
| Description | Mexiletine HCl belongs to Class IB anti-arrhythmic group of medicines, inhibits sodium channels to reduce the inward sodium current. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Mexiletine is a local anesthetic, antiarrhythmic agent (Class Ib), structurally similar to lidocaine, but orally active. Mexiletine, inhibits the inward sodium current required for the initiation and conduction of impulses, thus reducing the rate of rise of the action potential. It achieves this reduced sodium current by inhibiting sodium channels. Mexiletine decreases the effective refractory period (ERP) in Purkinje fibers in the heart. The decrease in ERP is of lesser magnitude than the decrease in action potential duration (APD), which results in an increase in the ERP/APD ratio. It does not significantly affect resting membrane potential or sinus node automaticity, left ventricular function, systolic arterial blood pressure, atrioventricular (AV) conduction velocity, or QRS or QT intervals. [1] |
|
| In vivo | Mexiletine has fast onset and offset kinetics, meaning that they have little or no effect at slower heart rates, and more effects at faster heart rates. It shortens the action potential duration, reduces refractoriness, and decreases Vmax in partially depolarized cells with fast response action potentials. Mexiletine either does not change the action potential duration, or decreases the action potential duration. Mexiletine is well absorbed (bioavailability 90%) from the gastrointenstinal tract. [2] |
Protocol
Solubility (25°C)
| In vitro | DMSO | 43 mg/mL (199.33 mM) |
|---|---|---|
| Water | 43 mg/mL (199.33 mM) | |
| Ethanol | 43 mg/mL (199.33 mM) |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 215.72 |
|---|---|
| Formula | C11H17NO.HCl |
| CAS No. | 5370-01-4 |
| Storage | powder |
| Synonyms | KO1173 |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02781454 | Recruiting | Sporadic Amyotrophic Lateral Sclerosis | University of Washington|Massachusetts General Hospital | October 2016 | Phase 2 |
| NCT02561702 | Active, not recruiting | Charcot Marie Tooth Disease | University of Rochester | September 2015 | Phase 2 |
| NCT02260388 | Recruiting | Cryptogenic Sensory Polyneuropathy | University of Kansas Medical Center|Patient-Centered Outcomes Research Institute | October 2014 | Phase 4 |
| NCT02308748 | Completed | Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics | Food and Drug Administration (FDA)|Spaulding Clinical Research LLC | May 2014 | Phase 1 |
| NCT02045667 | Completed | Non Dystrophic Myotonia | Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development | January 2014 | Phase 2 |
| NCT01849770 | Completed | Sporadic Amyotrophic Lateral Sclerosis | University of Washington | July 2013 | Phase 2 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
